Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 12/20 | 0.65 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782741 | 0.94 | SLC5A1 (0.73) | SLC5A1SLC5A2GAAP2RX3POLB | |
| SCHEMBL3767779 | 0.91 | SLC5A2 (0.54) | SLC5A1SLC5A2 | |
| SCHEMBL3769351 | 0.89 | SLC5A1 (0.51) | SLC5A1SLC5A2KDM4E | |
| SCHEMBL3767395 | 0.88 | SLC5A1 (0.51) | SLC5A1SLC5A2P2RX3 | |
| SCHEMBL3779163 | 0.86 | SLC5A2 (0.60) | SLC5A1SLC5A2 | |
| SCHEMBL3769872 | 0.86 | SLC5A2 (0.48) | SLC5A1SLC5A2LMNA | |
| SCHEMBL3778945 | 0.85 | SLC5A1 (0.47) | SLC5A1SLC5A2 | |
| SCHEMBL3771611 | 0.85 | SLC5A2 (0.47) | SLC5A1SLC5A2P2RX3 | |
| SCHEMBL2253384 | 0.84 | SLC5A2 (0.89) | SLC5A1SLC5A2 | |
| SCHEMBL3764892 | 0.83 | SLC5A1 (0.45) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | claimed |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | AJINOMOTO CO., INC. (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072813-A1 | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | IAPP, G6PC1, GPR119 | SLC5A1 4/4885SLC5A2 6/4885GAA 202/4885 |
| US-20100317575-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | SLC5A1, SLC5A2, G6PC1 | SLC5A1 1/4885SLC5A2 2/4885GAA 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.